This National Cancer Institute (NCI) grant is for the early-stage development of highly innovative technologies that enhance the quality of biospecimens used in basic and clinical cancer research, and clinical care. The focus is on creating new capabilities to address pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant samples. Supported technologies, including tools, devices, instrumentation, and associated methods, aim to preserve sample integrity or establish quality assessment/control criteria under various conditions. The ultimate goal is to maximize the utility of biological samples for downstream analyses, thereby accelerating and improving research across cancer biology, early detection, diagnosis, treatment, and health disparities by reducing pre-analytical variations.
Opportunity ID: 336429
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-22-003 |
| Funding Opportunity Title: | Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 04, 2021 |
| Last Updated Date: | Nov 04, 2021 |
| Original Closing Date for Applications: | Sep 22, 2022 |
| Current Closing Date for Applications: | Sep 22, 2022 |
| Archive Date: | Oct 28, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $150,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Independent school districts Special district governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities County governments City or township governments Public and State controlled institutions of higher education Small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-003.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 336429 Full Announcement-RFA-CA-22-003 -> RFA-CA-22-003-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270578 | Mar 22, 2022 | Sep 22, 2022 | View |
Package 1
Mandatory forms
336429 RR_SF424_5_0-5.0.pdf
336429 PHS398_CoverPageSupplement_5_0-5.0.pdf
336429 RR_OtherProjectInfo_1_4-1.4.pdf
336429 PerformanceSite_4_0-4.0.pdf
336429 RR_KeyPersonExpanded_4_0-4.0.pdf
336429 RR_Budget_3_0-3.0.pdf
336429 PHS398_ResearchPlan_4_0-4.0.pdf
336429 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336429 RR_SubawardBudget30_3_0-3.0.pdf
336429 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
